Continuing Education Activity

Klinefelter syndrome is a genetic condition characterized by the presence of 2 or more X chromosomes in a phenotypic male. The clinical features were first described in males with tall stature, small testes, gynecomastia, and azoospermia. The underlying genetic etiology—supernumerary X chromosomes—was identified in 1959. Additional X chromosomes contribute to testicular hyalinization, fibrosis, and hypofunction, often leading to hypogonadism, genital abnormalities, and infertility. Neurocognitive differences associated with Klinefelter syndrome were increasingly recognized during the mid-to-late 20th century. Androgen replacement, along with neuropsychological and adaptive therapies, frequently supports effective medical management.

In addition to infertility, individuals with Klinefelter syndrome are at increased risk for complications such as osteoporosis, metabolic syndrome, breast cancer, and autoimmune disorders. However, early diagnosis and comprehensive care, including hormonal, psychological, and educational support, can help many individuals achieve good long-term outcomes.

This activity for healthcare professionals is designed to enhance learners' competence in evaluating and managing Klinefelter syndrome. Participants broaden their grasp of the condition's genetics, pathophysiology, and clinical presentation. Current diagnostic and management recommendations are also discussed. Enhanced proficiency enables clinicians to collaborate more effectively within interprofessional teams, leading to improved outcomes for individuals with Klinefelter syndrome.

Objectives:

• Identify the clinical signs and diagnostic features indicative of Klinefelter syndrome.
• Select the appropriate diagnostic tools to evaluate Klinefelter syndrome.
• Implement personalized, evidence-based interventions for Klinefelter syndrome, focusing on hormonal treatments, speech and language therapies, and psychosocial support.
• Collaborate with an interprofessional healthcare team to provide comprehensive care for individuals with Klinefelter syndrome.

Introduction

Klinefelter syndrome is a genetic condition that affects males and is characterized by the presence of 2 or more X chromosomes. The clinical phenotype was first described in 1942 by American physician Dr. Harry Klinefelter.[1] Affected individuals often present with tall stature, small testes, gynecomastia, and azoospermia. The genetic etiology—supernumerary X chromosomes, typically 47,XXY—was identified in 1959.[2] Additional X chromosomes contribute to testicular hyalinization, fibrosis, and hypofunction, leading to genital abnormalities, most commonly hypogonadism and infertility.[3]

Neurocognitive differences began to gain broader recognition during the mid-to-late 20th century.[4] Androgen replacement, along with neuropsychological and adaptive therapies, often supports effective clinical management.[5][6] However, clinical care remains inconsistent due to delayed diagnosis, lack of standardized treatment protocols, and limited access to affordable therapies.

A similar but less common condition, Jacobs syndrome, is characterized by the 47,XYY genotype. Affected individuals are phenotypically male and may present with antisocial tendencies, asthma, autism, seizures, infertility, tall stature, macrocephaly, and hypertelorism. Please see StatPearls' companion resource, "Jacobs Syndrome," for further information.[7]

Etiology

The most common karyotype in Klinefelter syndrome is 47,XXY, accounting for >90% (see Image. Klinefelter Syndrome Karyotype). Mosaic karyotypes, such as 46,XY/47,XXY, and other aneuploidies, including 48,XXXY and 49,XXXXY, have also been reported. The acquisition of the extra X chromosome is random, typically resulting from meiotic nondisjunction or postzygotic nondisjunction.

Klinefelter syndrome typically arises from a de novo nondisjunction event rather than being inherited, though inherited cases have been reported. To date, 12 cases of healthy infants born to nonmosaic fathers with Klinefelter syndrome have been documented in the literature.

A 2020 case report by Ron-El et al described the retrieval of motile spermatozoa from a nonmosaic father with Klinefelter syndrome. After fertilizing 14 eggs, 3 embryos were transferred, resulting in a triplet pregnancy. Chorionic villus sampling revealed a chromosomal analysis of 46,XX, 46,XY, and 46,XXY. One fetus affected by the 46,XXY pattern was reduced during early pregnancy, leading to the birth of 1 boy and 1 girl with normal chromosomal patterns. The report emphasized the value of genetic testing.[8] The severity of the phenotype correlates with the amount of additional X chromosome material present.

Epidemiology

Klinefelter syndrome is the most common form of aneuploidy, characterized by an abnormal number of chromosomes in the affected individual's cells. The estimated prevalence is between 1 in 500 and 1 in 1000 males.[9] Diagnosis often occurs in adulthood, as many cases remain unidentified until later in life. Recognition often begins during evaluation for specific clinical features across different life stages, such as in the following:

• Prenatal testing or observation of genital abnormalities in a newborn with hypotonia
• Documentation of learning or behavioral difficulties in an adolescent
• Evaluation for tall stature, small testicular size, or incomplete puberty in an adolescent
• Evaluation for infertility (3% of men evaluated for infertility have Klinefelter syndrome) or hypogonadism in a male adult

Up to two-thirds of individuals with Klinefelter syndrome remain undiagnosed.[10] Comparative studies suggest that Klinefelter syndrome may occur more frequently with advancing parental age, environmentally derived errors in meiosis I, or a decrease in elective terminations for prenatally diagnosed cases. Underdiagnosis is likely due to the variable phenotype, with many cases presenting with only subtle features.

An estimated quarter of individuals with Klinefelter syndrome show no discernible diagnostic features based on history or examination. With the increased use of noninvasive prenatal testing, the frequency of prenatal diagnosis is expected to rise, enabling early management by pediatricians.

Fewer than 10% of cases are detected before puberty, and only 26% to 37% are identified overall, with most remaining undiagnosed.[11][12][13] The average age of diagnosis is 30 years, and the median lifespan is reduced by 5 or 6 years compared to the general male population.[14][15]

Pathophysiology

The molecular mechanisms underlying primary testicular failure and the phenotypic heterogeneity of physical and neurocognitive features in Klinefelter syndrome remain poorly characterized. Ongoing studies attempt to determine the influence of genetic polymorphisms, skewed X-inactivation, the parental origin of the extra X chromosome, and gene dosage.

Additional X chromosome material contributes to testicular hyalinization and fibrosis, leading to primary gonadal failure that often progresses through adolescence and young adulthood. The prevalence of hypogonadism in adult males with Klinefelter syndrome ranges from 65% to 85%.[16]

The condition may manifest in newborns with microphallus, hypospadias, cryptorchidism, and small testes. Later, evolving hypogonadism results in incomplete puberty and gynecomastia. In adults, long-term hypogonadism and infertility are typical clinical manifestations.

Decreased bone density is more common in men with Klinefelter syndrome compared to men without this condition. Osteoporosis occurs in 6% to 15% of individuals, whereas osteopenia affects 25% to 48% of individuals.[17] This presentation typically begins in adolescence and results from a higher rate of bone resorption combined with decreased bone formation. Although hypogonadism partially explains this occurrence, other factors, such as reduced vitamin D levels, also play a role.[18]

The additional gene dosage of the SHOX gene in the pseudoautosomal region of the X chromosome contributes to tall stature, long limbs, and a reduced upper-lower segment ratio. The pathophysiology of neuropsychological differences observed in Klinefelter syndrome remains poorly understood.

Histopathology

In Klinefelter syndrome, the seminiferous tubules exhibit hyalinization and fibrosis in the context of gonadotropin excess, leading to firm, often undersized testes. Limited studies of testicular biopsies from individuals with Klinefelter syndrome show a reduced number of germ cells across the lifespan, with a progressive decline, particularly after puberty. In adulthood, only infrequent pockets of spermatogonia are observed.[19][20]

History and Physical

Most individuals with Klinefelter syndrome present with tall stature and long limbs, reflected in a low upper-to-lower segment ratio. Mean height typically falls at the 75th percentile, whereas weight and head circumference align with the 50th percentile. In childhood, the phallus and testes may appear relatively small (<1.9 cm). During adolescence, puberty often progresses in a discordant manner, with normal phallic growth and pubic hair development. However, the testes rarely exceed a volume of 4 mL and are characteristically firm due to hyalinization and fibrosis. Testosterone concentrations typically fall within the low to low-normal range. Gynecomastia is common, and affected individuals are at an increased risk of developing male breast cancer.[21]

A wide range of intelligence quotients (IQs) has been reported. However, the mean full-scale IQ falls between 85 and 90, with an average reduction of approximately 15 points.[22] Verbal difficulties often stem from deficits in expressive language and auditory processing.[23] Behavioral features may include immaturity, insecurity, shyness, poor judgment, and attention deficit hyperactivity disorder. Individuals with Klinefelter syndrome are at a higher risk of anxiety and depression, often related to body image concerns, interpersonal challenges, and infertility.[24][25][26][27] 

Between 20% and 50% of individuals with Klinefelter syndrome experience intention tremors. Approximately 10% of affected males meet the criteria for autism spectrum disorder, supporting the need for routine autism screening in this population.[28]

Around two-thirds of individuals with Klinefelter syndrome require remedial speech therapy for language deficits. Any male receiving speech and language therapy should be evaluated for Klinefelter syndrome.[29] Additional complications may involve multiple organ systems, often identified during history and physical examination. (Please refer to the Complications section for more information.)

Evaluation

The initial evaluation of Klinefelter syndrome often involves assessing for hypogonadism or infertility. Levels of the gonadotropins—follicle-stimulating hormone (FSH) and luteinizing hormone (LH)—are typically elevated in the setting of testicular hyalinization and fibrosis. However, this hormonal pattern may evolve throughout adolescence. Hypergonadotropic hypogonadism reflects primary gonadal failure.[30]

FSH levels typically exceed those of LH, although both are elevated above normal ranges. Testosterone concentrations are typically low or low-normal in adolescents and adults. Elevated sex hormone–binding globulin levels reduce free serum testosterone, even when total testosterone appears within normal limits. Most adults with Klinefelter syndrome exhibit hypogonadism, although not universally. Serum estradiol concentrations are often high-normal or elevated, and the estradiol-to-testosterone ratio remains consistently increased, contributing to gynecomastia.[31]

Inhibin B is typically undetectable, and anti-Müllerian hormone levels are typically low in adults with Klinefelter syndrome, reflecting abnormal Sertoli cell function.[32][33][34] Both biomarkers typically remain within normal ranges during childhood but become abnormal after puberty.

Noninvasive prenatal testing for cell-free fetal DNA can detect sex chromosome abnormalities. Published positive predictive values for identifying Klinefelter syndrome through noninvasive prenatal testing range from 67% to 78%.[35] Noninvasive prenatal testing analyzes small fragments of fetal DNA circulating in maternal serum.[36] Any suspected case requires additional prenatal or postnatal testing for confirmation.

A definitive diagnosis of Klinefelter syndrome typically involves prenatal or postnatal karyotype analysis or chromosomal microarray testing. Referral to a reference laboratory with expertise in these examinations is recommended. Confirmation by karyotyping requires analysis of at least 20 cultured metaphase lymphocytes.[37] Using fluorescence in situ hybridization can improve diagnostic accuracy.[38]

A baseline dual-energy X-ray absorptiometry scan is recommended due to the higher prevalence of reduced bone mineral density and increased risk of osteoporosis in affected individuals. Contributing factors include hypogonadism, vitamin D deficiency, and altered bone remodeling.

Treatment / Management

Earlier diagnosis, often prenatally, allows timely developmental evaluation and early intervention to support neuropsychological outcomes. Speech-language and motor delays affect 50% to 75% of individuals, warranting proactive screening and early therapy. Unaddressed speech delays can impair self-expression, reduce frustration tolerance, and contribute to behavioral challenges. Hypotonia, hypermobility, pes planus, and genu valgum may interfere with motor milestones, such as handwriting and self-care, requiring physical or occupational therapy and adaptive interventions, including orthotics. Common behavioral and mental health concerns include anxiety and depression, and referral to behavioral health services can provide substantial benefit.

Supervised testosterone supplementation by a pediatric endocrinologist may mitigate physical manifestations traditionally associated with this condition. Hypogonadism often begins in utero, contributing to underdeveloped genitalia, cryptorchidism, reduced germ cell populations, small testes, and an attenuated minipuberty in infancy. Some healthcare providers administer testosterone during the first few postnatal months to treat microphallus. Retrospective data suggest potential cognitive and behavioral benefits, although prospective studies are ongoing.[39][40]

Infants with cryptorchidism or an inguinal hernia should undergo appropriate surgical intervention. The American Urological Association does not recommend hormonal treatment for cryptorchidism due to its low success rate and the lack of evidence supporting long-term benefits.[41] However, some clinicians argue that hormonal therapy poses minimal risk, may enhance future fertility, and could eliminate the need for surgery in a select subset of patients.[42][43][44]

All affected individuals should undergo screening for autism spectrum disorder. Additional concerns may include impaired bone mineralization, significantly delayed language skills, diabetes mellitus, hypogonadism, and infertility. Metabolic syndrome—often associated with hypogonadism and obesity—affects approximately 44% of affected individuals.

During adolescence, most individuals enter puberty spontaneously, with endogenous testosterone supporting virilization, including normal penile growth and pubic hair development. However, reduced facial and body hair may be noted. Supplemental testosterone can reduce the severity of gynecomastia, which frequently emerges during adolescence. Other management options for gynecomastia, such as aromatase inhibitors (ineffective), tamoxifen (with limited data), or surgery (invasive and prone to recurrence), offer limited or inconsistent benefits.[45]

Testosterone plays a crucial role in bone growth and skeletal health in males. Early hormonal therapy may help prevent bone loss and reduce the risk of decreased bone mineral density.[46] Individuals with osteopenia or osteoporosis tend to respond well to treatment with testosterone, calcium, and vitamin D, particularly when therapy is sustained over an extended period.[47][48] In cases of significant demineralization, bisphosphonates or inhibitors of the receptor activator of nuclear factor κB ligand are often required. Treatment outcomes in individuals with Klinefelter syndrome are generally comparable to those observed in other populations with bone loss. Please see StatPearls' companion resource, "Osteoporosis in Males," for further information.

To ensure appropriate education, rapport, and a structured plan for monitoring and treatment, boys and their parents should engage with a pediatric endocrinologist around the onset of puberty. The decision to initiate androgen replacement should be individualized and may begin with the onset of puberty or be delayed until clear signs of hypogonadism emerge, which may not occur until late adolescence or early adulthood. Guidelines for hormone replacement in males with hypogonadism are available from the Endocrine Society and the American Urological Association.[49][50] Please see StatPearls' companion resource, "Male Hypogonadism," for further information.

Advanced reproductive technology, such as microsurgical testicular sperm extraction, has enabled up to 50% of men previously deemed infertile due to Klinefelter syndrome to father biological children.[51][52] Small pockets of sperm-producing gonadal tissue can be identified, extracted, and used for fertilization through intracytoplasmic sperm injection.

Long-term health risks in individuals with Klinefelter syndrome include conditions related to insulin resistance, such as type 2 diabetes, dyslipidemia, fatty liver disease, peripheral vascular disease, and thromboembolic disease. Careful screening and proactive preventive care are strongly recommended. Bone mineral density often declines, likely due to hypogonadism, underscoring the importance of ongoing assessment of skeletal health. Some studies also report higher rates of autoimmune disorders.

There is also an elevated risk for certain malignancies, including breast cancer, extragonadal germ cell tumors, and non-Hodgkin lymphoma.[53] Although these cancers remain rare, any concerning symptoms should prompt thorough evaluation.

Differential Diagnosis

The differential diagnosis for Klinefelter syndrome includes a range of conditions with overlapping clinical features. These clinical entities include both genetic syndromes and endocrinological disorders that can mimic or coexist with the phenotype of Klinefelter syndrome.

• Acromegaly
• Adrenogenital and gonadal-secreting tumors
• Azoospermia
• Beckwith-Wiedemann syndrome
• Constitutional gigantism
• Diabetes mellitus
• Fragile X syndrome
• Hyperprolactinemia
• Hypogonadism
• Male infertility
• Marfan syndrome
• Mosaicism
• Neurofibromatosis
• Primary testicular failure
• Sanfilippo syndrome
• Simpson-Rosan-Golabi syndrome

Accurate diagnosis requires careful consideration of these differential conditions through a comprehensive clinical evaluation, genetic testing, and appropriate screening. Early identification ensures effective management and intervention, improving outcomes for individuals affected by these syndromes.

Prognosis

Although Klinefelter syndrome cannot be cured, early diagnosis and appropriate testosterone replacement therapy can alleviate many of its adverse effects and complications. Testosterone replacement supports the development of male secondary sexual characteristics, improves bone density, and enhances focus, mood, and attention. In some cases, assisted reproductive technologies can restore fertility. However, despite these interventions, individuals with Klinefelter syndrome typically have a shortened lifespan of about 5 to 6 years.

Complications

Individuals with Klinefelter syndrome are at an increased risk for several disorders. These risks span multiple organ systems, necessitating an interprofessional approach to care.[54]

Reproductive Issues

Androgen deficiency and testicular failure are central to reproductive abnormalities in Klinefelter syndrome. Common features include azoospermia, infertility, small testes, small penis size (<8 cm), low libido, testicular failure, and gynecomastia. Sparse facial and body hair is another distinguishing trait. These issues are linked to impaired spermatogenesis, and affected individuals typically experience challenges in achieving biological paternity.

Behavioral and Neurodevelopmental Effects

Behavioral issues are also prevalent in individuals with Klinefelter syndrome. Anxiety, depression, attention deficit hyperactivity disorder, relationship issues, and autism spectrum disorder are commonly reported. Lower IQ and learning disabilities are also observed in some affected individuals.

Metabolic Abnormalities

Low testosterone levels, increased visceral fat, and greater waist circumference are associated with the elevated prevalence of type 2 diabetes in individuals with Klinefelter syndrome. Increased visceral fat in the abdominal area increases the risk of diabetes mellitus.[55] Metabolic complications also include hypertension, hyperlipidemia, and low high-density lipoprotein levels. These factors often co-occur with obesity and further increase the likelihood of cardiovascular disease.

Oncologic Complications

Individuals with Klinefelter syndrome are at elevated risk for certain cancers. A hormonal etiology has been proposed as the cause of higher rates of breast and prostate cancers. The risk of germ cell tumors, non-Hodgkin lymphoma, and lung cancer is also increased.[56]

Endocrinologic Disorders

Klinefelter syndrome is also associated with hypopituitarism, which can present with symptoms such as headaches, blurred vision, and dizziness. Individuals with this condition may experience either partial or complete hypopituitarism, which can affect multiple pituitary hormones, including growth hormone and thyroid-stimulating hormone. A case report by Rehman et al in 2018 described an individual diagnosed with Klinefelter syndrome and hypogonadism who was also found to have low levels of pituitary hormones, suggesting hypopituitarism (Endocrine Abstracts. A rare case of primary hypogonadism and partial hypopituitarism in klinefelter syndrome).

Musculoskeletal Issues

Musculoskeletal abnormalities in Klinefelter syndrome are attributed to chromosomal, hormonal, and growth-related factors. The extra X chromosome affects genes involved in bone elongation, leading to taller stature and longer legs. Delayed epiphyseal closure from testosterone deficiency causes eunuchoidal proportions. Hypogonadism reduces muscle mass and bone density, whereas normal or elevated growth hormone levels contribute to taller stature. Osteopenia and osteoporosis result from testosterone deficiency, which impairs bone formation and increases resorption. Altered vitamin D metabolism and reduced insulin-like peptide 3 levels further affect bone health. Although testosterone replacement therapy and physical rehabilitation can improve muscle mass and bone density, these interventions may not fully reverse the musculoskeletal features.

Associated Autoimmune Conditions

Individuals with Klinefelter syndrome appear to have an increased susceptibility to autoimmune diseases, potentially due to the presence of an extra X chromosome and associated hormonal imbalances. Reported conditions include systemic lupus erythematosus, rheumatoid arthritis, and autoimmune thyroid disorders, such as nodular thyroid disease. Type 1 diabetes, although less frequently recognized, has also been documented in individuals with Klinefelter syndrome. Sakurai et al described a case of Klinefelter syndrome coexisting with type 1 diabetes, highlighting the importance of routine screening for autoimmune endocrinopathies in this population.[57]

Vascular and Thromboembolic Complications

Individuals with Klinefelter syndrome have an elevated risk of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and varicose veins. This risk arises from a combination of procoagulant imbalances, hormonal factors such as testosterone deficiency, and X-linked genetic influences. Thrombophilia screening and careful monitoring are recommended, especially during testosterone therapy or periods of immobilization.

Deterrence and Patient Education

Once the diagnosis of Klinefelter syndrome is confirmed, individuals and their families should receive clear education about the condition. Clinicians should emphasize that Klinefelter syndrome is the result of a random genetic event, is not inherited, and could not have been prevented. Klinefelter syndrome is a genetic condition, not a disease, and while it cannot be cured, effective treatments are available to reduce its impact. With appropriate care, many features can be managed successfully. In many cases, fertility can now be restored using assisted reproductive technologies. Please see StatPearls' companion resources, "Male Infertility," "Assisted Reproductive Technology (ART) Techniques," and "In Vitro Fertilization," for further information.

Pearls and Other Issues

The most important points to remember when evaluating and managing Klinefelter syndrome include the following:

• Early diagnosis of Klinefelter syndrome has become more accessible, enabling timely intervention and better outcomes.
• Pediatricians should consider Klinefelter syndrome in phenotypic males presenting with developmental delays or small genitalia. Evaluation is also warranted in boys diagnosed with autism spectrum disorder or those presenting with speech and language difficulties.
• Diagnosis during infancy permits optional short-term testosterone therapy before 1 year of age to promote penile growth in cases of micropenis.[58][59][60]
• Hypogonadism, infertility, and small, firm testes define the classic adult presentation. Confirmatory testing requires karyotyping.
• Initiating testosterone replacement early remains the cornerstone of treatment.
• Fertility restoration is achievable in many individuals with Klinefelter syndrome through advanced assisted reproductive technologies.

Managing Klinefelter syndrome requires coordinated interprofessional care involving pediatricians, endocrinologists, geneticists, fertility specialists, and mental health professionals. Timely collaboration across specialties ensures comprehensive treatment that addresses hormonal, developmental, reproductive, and psychosocial needs.

Enhancing Healthcare Team Outcomes

Individuals with Klinefelter syndrome benefit significantly from coordinated, interprofessional care involving endocrinologists, urologists, neurologists, psychiatrists, geneticists, internists, pediatricians, psychologists, speech therapists, and physical therapists. This collaborative approach provides patient and caregiver education on testosterone-related adverse effects, ensures proper administration, and oversees necessary follow-up testing and monitoring. Reproductive endocrinologists and urologists specializing in male infertility may also contribute to fertility planning and management.

As individuals age, careful monitoring becomes essential to address risks such as type 2 diabetes, fatty liver, breast cancer, bone mineral density loss, and dyslipidemia. Primary care providers, including nurse practitioners, play a key role in ongoing assessments due to increased susceptibility to malignancy and chronic disease.

Long-term outcomes vary depending on mental health, with a slightly shorter lifespan than the general population. Sustained, interprofessional involvement offers the best opportunity to optimize both health and quality of life.[61]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA, Ferlin A., Klinefelter ItaliaN Group (KING). Klinefelter syndrome (KS): genetics, clinical phenotype and hypogonadism. J Endocrinol Invest. 2017 Feb;40(2):123-134. [PMC free article: PMC5269463] [PubMed: 27644703]

2.

JACOBS PA, STRONG JA. A case of human intersexuality having a possible XXY sex-determining mechanism. Nature. 1959 Jan 31;183(4657):302-3. [PubMed: 13632697]

3.

Belling K, Russo F, Jensen AB, Dalgaard MD, Westergaard D, Rajpert-De Meyts E, Skakkebæk NE, Juul A, Brunak S. Klinefelter syndrome comorbidities linked to increased X chromosome gene dosage and altered protein interactome activity. Hum Mol Genet. 2017 Apr 01;26(7):1219-1229. [PMC free article: PMC5390676] [PubMed: 28369266]

4.

Daly RF. Mental illness and patterns of behavior in 10 XXY males. J Nerv Ment Dis. 1969 Oct;149(4):318-27. [PubMed: 5383603]

5.

Davis S, Howell S, Wilson R, Tanda T, Ross J, Zeitler P, Tartaglia N. Advances in the Interdisciplinary Care of Children with Klinefelter Syndrome. Adv Pediatr. 2016 Aug;63(1):15-46. [PMC free article: PMC5340500] [PubMed: 27426894]

6.

Ross JL, Kushner H, Kowal K, Bardsley M, Davis S, Reiss AL, Tartaglia N, Roeltgen D. Androgen Treatment Effects on Motor Function, Cognition, and Behavior in Boys with Klinefelter Syndrome. J Pediatr. 2017 Jun;185:193-199.e4. [PMC free article: PMC6754744] [PubMed: 28285751]

7.

Sood B, Clemente Fuentes RW. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Sep 10, 2024. Jacobs Syndrome. [PubMed: 32491631]

8.

Ron-El R, Strassburger D, Gelman-Kohan S, Friedler S, Raziel A, Appelman Z. A 47,XXY fetus conceived after ICSI of spermatozoa from a patient with non-mosaic Klinefelter's syndrome: case report. Hum Reprod. 2000 Aug;15(8):1804-6. [PubMed: 10920107]

9.

Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab. 2003 Feb;88(2):622-6. [PubMed: 12574191]

10.

Herlihy AS, Halliday JL, Cock ML, McLachlan RI. The prevalence and diagnosis rates of Klinefelter syndrome: an Australian comparison. Med J Aust. 2011 Jan 03;194(1):24-8. [PubMed: 21449864]

11.

Akcan N, Poyrazoğlu Ş, Baş F, Bundak R, Darendeliler F. Klinefelter Syndrome in Childhood: Variability in Clinical and Molecular Findings. J Clin Res Pediatr Endocrinol. 2018 Jun 01;10(2):100-107. [PMC free article: PMC5985377] [PubMed: 29022558]

12.

Swerdlow AJ, Hermon C, Jacobs PA, Alberman E, Beral V, Daker M, Fordyce A, Youings S. Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study. Ann Hum Genet. 2001 Mar;65(Pt 2):177-88. [PubMed: 11427177]

13.

Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care. 2006 Jul;29(7):1591-8. [PubMed: 16801584]

14.

Groth KA, Skakkebæk A, Høst C, Gravholt CH, Bojesen A. Clinical review: Klinefelter syndrome--a clinical update. J Clin Endocrinol Metab. 2013 Jan;98(1):20-30. [PubMed: 23118429]

15.

Gravholt CH, Chang S, Wallentin M, Fedder J, Moore P, Skakkebæk A. Klinefelter Syndrome: Integrating Genetics, Neuropsychology, and Endocrinology. Endocr Rev. 2018 Aug 01;39(4):389-423. [PubMed: 29438472]

16.

Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter's syndrome. Lancet. 2004 Jul 17-23;364(9430):273-83. [PubMed: 15262106]

17.

Grande G, Graziani A, Di Mambro A, Selice R, Ferlin A. Osteoporosis and bone metabolism in patients with Klinefelter syndrome. Endocr Connect. 2023 Jul 05;12(8) [PMC free article: PMC10388662] [PubMed: 37166398]

18.

Ferlin A, Selice R, Di Mambro A, Ghezzi M, Di Nisio A, Caretta N, Foresta C. Role of vitamin D levels and vitamin D supplementation on bone mineral density in Klinefelter syndrome. Osteoporos Int. 2015 Aug;26(8):2193-202. [PubMed: 25963234]

19.

Corona G, Pizzocaro A, Lanfranco F, Garolla A, Pelliccione F, Vignozzi L, Ferlin A, Foresta C, Jannini EA, Maggi M, Lenzi A, Pasquali D, Francavilla S., Klinefelter ItaliaN Group (KING). Sperm recovery and ICSI outcomes in Klinefelter syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2017 May 01;23(3):265-275. [PubMed: 28379559]

20.

Chehrazi M, Rahimiforoushani A, Sabbaghian M, Nourijelyani K, Sadighi Gilani MA, Hoseini M, Vesali S, Yaseri M, Alizadeh A, Mohammad K, Samani RO. Sperm Retrieval in Patients with Klinefelter Syndrome: A Skewed Regression Model Analysis. Int J Fertil Steril. 2017 Jul-Sep;11(2):117-122. [PMC free article: PMC5347449] [PubMed: 28670430]

21.

Kanakis GA, Nieschlag E. Klinefelter syndrome: more than hypogonadism. Metabolism. 2018 Sep;86:135-144. [PubMed: 29382506]

22.

Linden MG, Bender BG, Robinson A. Sex chromosome tetrasomy and pentasomy. Pediatrics. 1995 Oct;96(4 Pt 1):672-82. [PubMed: 7567329]

23.

Simpson NH, Addis L, Brandler WM, Slonims V, Clark A, Watson J, Scerri TS, Hennessy ER, Bolton PF, Conti-Ramsden G, Fairfax BP, Knight JC, Stein J, Talcott JB, O'Hare A, Baird G, Paracchini S, Fisher SE, Newbury DF., SLI Consortium. Increased prevalence of sex chromosome aneuploidies in specific language impairment and dyslexia. Dev Med Child Neurol. 2014 Apr;56(4):346-53. [PMC free article: PMC4293460] [PubMed: 24117048]

24.

Srinivasan R, Wolstencroft J, Erwood M, Raymond FL, van den Bree M, Hall J, Skuse D., IMAGINE ID Consortium. Mental health and behavioural problems in children with XXYY: a comparison with intellectual disabilities. J Intellect Disabil Res. 2019 May;63(5):477-488. [PubMed: 30993819]

25.

St John M, Ponchard C, van Reyk O, Mei C, Pigdon L, Amor DJ, Morgan AT. Speech and language in children with Klinefelter syndrome. J Commun Disord. 2019 Mar-Apr;78:84-96. [PubMed: 30822601]

26.

van Rijn S, Swaab H. Executive dysfunction and the relation with behavioral problems in children with 47,XXY and 47,XXX. Genes Brain Behav. 2015 Feb;14(2):200-8. [PubMed: 25684214]

27.

Bishop DV, Jacobs PA, Lachlan K, Wellesley D, Barnicoat A, Boyd PA, Fryer A, Middlemiss P, Smithson S, Metcalfe K, Shears D, Leggett V, Nation K, Scerif G. Autism, language and communication in children with sex chromosome trisomies. Arch Dis Child. 2011 Oct;96(10):954-9. [PMC free article: PMC3182523] [PubMed: 20656736]

28.

Jha P, Sheth D, Ghaziuddin M. Autism spectrum disorder and Klinefelter syndrome. Eur Child Adolesc Psychiatry. 2007 Aug;16(5):305-8. [PubMed: 17401614]

29.

Butler G, Srirangalingam U, Faithfull J, Sangster P, Senniappan S, Mitchell R. Klinefelter syndrome: going beyond the diagnosis. Arch Dis Child. 2023 Mar;108(3):166-171. [PMC free article: PMC7614197] [PubMed: 35948402]

30.

Sizar O, Leslie SW, Schwartz J. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 25, 2024. Male Hypogonadism. [PubMed: 30422528]

31.

Maseroli E, Rastrelli G, Corona G, Boddi V, Amato AM, Mannucci E, Forti G, Maggi M. Gynecomastia in subjects with sexual dysfunction. J Endocrinol Invest. 2014 Jun;37(6):525-32. [PubMed: 24515298]

32.

Christiansen P, Andersson AM, Skakkebaek NE. Longitudinal studies of inhibin B levels in boys and young adults with Klinefelter syndrome. J Clin Endocrinol Metab. 2003 Feb;88(2):888-91. [PubMed: 12574229]

33.

Anawalt BD, Bebb RA, Matsumoto AM, Groome NP, Illingworth PJ, McNeilly AS, Bremner WJ. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab. 1996 Sep;81(9):3341-5. [PubMed: 8784094]

34.

Aksglaede L, Christiansen P, Sørensen K, Boas M, Linneberg A, Main KM, Andersson AM, Skakkebaek NE, Juul A. Serum concentrations of Anti-Müllerian Hormone (AMH) in 95 patients with Klinefelter syndrome with or without cryptorchidism. Acta Paediatr. 2011 Jun;100(6):839-45. [PubMed: 21251056]

35.

Zhang B, Lu BY, Yu B, Zheng FX, Zhou Q, Chen YP, Zhang XQ. Noninvasive prenatal screening for fetal common sex chromosome aneuploidies from maternal blood. J Int Med Res. 2017 Apr;45(2):621-630. [PMC free article: PMC5536640] [PubMed: 28357876]

36.

Skrzypek H, Hui L. Noninvasive prenatal testing for fetal aneuploidy and single gene disorders. Best Pract Res Clin Obstet Gynaecol. 2017 Jul;42:26-38. [PubMed: 28342726]

37.

Wiktor AE, Bender G, Van Dyke DL. Identification of sex chromosome mosaicism: is analysis of 20 metaphase cells sufficient? Am J Med Genet A. 2009 Feb;149A(2):257-9. [PubMed: 19161142]

38.

Abdelmoula NB, Amouri A, Portnoi MF, Saad A, Boudawara T, Mhiri MN, Bahloul A, Rebai T. Cytogenetics and fluorescence in situ hybridization assessment of sex-chromosome mosaicism in Klinefelter's syndrome. Ann Genet. 2004 Apr-Jun;47(2):163-75. [PubMed: 15183749]

39.

Samango-Sprouse C, Lasutschinkow P, Powell S, Sadeghin T, Gropman A. The incidence of anxiety symptoms in boys with 47,XXY (Klinefelter syndrome) and the possible impact of timing of diagnosis and hormonal replacement therapy. Am J Med Genet A. 2019 Mar;179(3):423-428. [PubMed: 30637954]

40.

Samango-Sprouse C, Stapleton EJ, Lawson P, Mitchell F, Sadeghin T, Powell S, Gropman AL. Positive effects of early androgen therapy on the behavioral phenotype of boys with 47,XXY. Am J Med Genet C Semin Med Genet. 2015 Jun;169(2):150-7. [PubMed: 25939399]

41.

Kolon TF, Herndon CD, Baker LA, Baskin LS, Baxter CG, Cheng EY, Diaz M, Lee PA, Seashore CJ, Tasian GE, Barthold JS., American Urological Assocation. Evaluation and treatment of cryptorchidism: AUA guideline. J Urol. 2014 Aug;192(2):337-45. [PubMed: 24857650]

42.

Hadziselimovic F. Opinion: Comment on Evaluation and Treatment of Cryptorchidism: AUA/AAP and Nordic Consensus Guidelines. Urol Int. 2016;96(3):249-54. [PubMed: 26824668]

43.

Hadziselimović F, Huff D, Duckett J, Herzog B, Elder J, Snyder H, Buser M. Long-term effect of luteinizing hormone-releasing hormone analogue (buserelin) on cryptorchid testes. J Urol. 1987 Oct;138(4 Pt 2):1043-5. [PubMed: 2888905]

44.

Radmayr C, Dogan HS, Hoebeke P, Kocvara R, Nijman R, Silay S, Stein R, Undre S, Tekgul S. Management of undescended testes: European Association of Urology/European Society for Paediatric Urology Guidelines. J Pediatr Urol. 2016 Dec;12(6):335-343. [PubMed: 27687532]

45.

Vandeven HA, Pensler JM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Gynecomastia. [PubMed: 28613563]

46.

Ferlin A, Selice R, Carraro U, Foresta C. Testicular function and bone metabolism--beyond testosterone. Nat Rev Endocrinol. 2013 Sep;9(9):548-54. [PubMed: 23856820]

47.

Corona G, Vena W, Pizzocaro A, Giagulli VA, Francomano D, Rastrelli G, Mazziotti G, Aversa A, Isidori AM, Pivonello R, Vignozzi L, Mannucci E, Maggi M, Ferlin A. Testosterone supplementation and bone parameters: a systematic review and meta-analysis study. J Endocrinol Invest. 2022 May;45(5):911-926. [PubMed: 35041193]

48.

Kübler A, Schulz G, Cordes U, Beyer J, Krause U. The influence of testosterone substitution on bone mineral density in patients with Klinefelter's syndrome. Exp Clin Endocrinol. 1992;100(3):129-32. [PubMed: 1305064]

49.

Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 May 01;103(5):1715-1744. [PubMed: 29562364]

50.

Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018 Aug;200(2):423-432. [PubMed: 29601923]

51.

Leslie SW, Soon-Sutton TL, Khan MAB. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 25, 2024. Male Infertility. [PubMed: 32965929]

52.

Sá R, Ferraz L, Barros A, Sousa M. The Klinefelter Syndrome and Testicular Sperm Retrieval Outcomes. Genes (Basel). 2023 Mar 04;14(3) [PMC free article: PMC10048758] [PubMed: 36980920]

53.

Hasle H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefelter syndrome. Br J Cancer. 1995 Feb;71(2):416-20. [PMC free article: PMC2033611] [PubMed: 7841064]

54.

di Fraia R, Esposito D, Selvaggio LD, Allosso F, Alfano R, Rotondi M, Balercia G, Accardo G, Pasquali D. Increased prevalence of nodular thyroid disease in patients with Klinefelter syndrome. Endocrine. 2023 Sep;81(3):631-636. [PMC free article: PMC10403437] [PubMed: 37148417]

55.

O'Connor MJ, Snyder EA, Hayes FJ. Klinefelter Syndrome and Diabetes. Curr Diab Rep. 2019 Jul 31;19(9):71. [PubMed: 31367971]

56.

Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA., UK Clinical Cytogenetics Group. Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst. 2005 Aug 17;97(16):1204-10. [PubMed: 16106025]

57.

Sakurai T, Iizuka K, Kato T, Takeda J. Type 1 Diabetes Mellitus and Klinefelter Syndrome. Intern Med. 2019 Jan 15;58(2):259-262. [PMC free article: PMC6378147] [PubMed: 30146555]

58.

Wiygul J, Palmer LS. Micropenis. ScientificWorldJournal. 2011 Jul 28;11:1462-9. [PMC free article: PMC5720072] [PubMed: 21805015]

59.

Hatipoğlu N, Kurtoğlu S. Micropenis: etiology, diagnosis and treatment approaches. J Clin Res Pediatr Endocrinol. 2013;5(4):217-23. [PMC free article: PMC3890219] [PubMed: 24379029]

60.

Khadilkar V, Mondkar SA. Micropenis. Indian J Pediatr. 2023 Jun;90(6):598-604. [PubMed: 37079255]

61.

Thyen U, Ittermann T, Flessa S, Muehlan H, Birnbaum W, Rapp M, Marshall L, Szarras-Capnik M, Bouvattier C, Kreukels BPC, Nordenstroem A, Roehle R, Koehler B., dsd-LIFE group. Quality of health care in adolescents and adults with disorders/differences of sex development (DSD) in six European countries (dsd-LIFE). BMC Health Serv Res. 2018 Jul 05;18(1):527. [PMC free article: PMC6034291] [PubMed: 29976186]

Disclosure: Evan Los declares no relevant financial relationships with ineligible companies.

Disclosure: Stephen Leslie declares no relevant financial relationships with ineligible companies.

Disclosure: Sandhya Kadam declares no relevant financial relationships with ineligible companies.

Disclosure: George Ford declares no relevant financial relationships with ineligible companies.